Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in previously treated unresectable or metastatic melanoma
ACTRN12605000684628Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sorafenib in melanoma, sponsored by Bayer. Started May 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12605000684628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000684628.